Aktie A2JRKN ASCLETIS PHARMA INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Ascletis Pharma Inc.

Aktien

A2JRKN

KYG0520K1094

1672

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:05 31.05.2024 		% 5 Tage % 1. Jan.
1.21 HKD -0.82% Intraday Chart für Ascletis Pharma Inc. -3.97% -17.12%
03.04. Ascletis stellt Studien mit dem FXR-Agonisten gegen biliäre Cholangitis, NASH und Hepatitis-B-Virus ein MT
03.04. Ascletis Pharma Inc. gibt strategische Entscheidungen zum FXR-Agonisten ASC42 bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis
Ascletis Pharma Gets Nod to Trial Acne Drug
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease Meet
Ascletis Pharma Publishes Results of Gannex's Fatty Liver Medication
Ascletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne Drug
Ascletis Pharma Finds Envafolimab Safe to Use in Study
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
Ascletis Enrolls 120 Patients in Phase 3 Clinical Trial for Combination Treatment for Glioblastoma; Shares Fall 6%
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
Ascletis' H1 Attributable Loss Narrows as Revenue Jumps
Ascletis Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Ascletis Pharma's HIV Drug Clinical Data Presented at Australia Medical Conference
Ascletis Unit Completes Patient Enrollment for Phase 2 Trial for Biliary Cholangitis Drug; Shares Rise 8%
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2JRKN Aktie
  4. Nachrichten Ascletis Pharma Inc.
  5. Andere Sprachen